Engineered immune cells take on recurrent brain tumors in early trial
NCT ID NCT06964737
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new type of immunotherapy called anti-GARP CAR T-cell therapy for people with recurrent high-grade gliomas (aggressive brain tumors). Researchers will take a patient's own immune cells, modify them in the lab to target a protein called GARP found on tumor cells, and then infuse them back into the brain. The main goals are to find the safest dose and to see if the treatment is tolerable, with 30 participants enrolled at a single medical center.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anti-GARP CAR T-cells
- What this could lead to
- If this works, it could point toward a new treatment option for recurrent high-grade gliomas, a type of brain cancer with few effective therapies.
- What could go wrong
- This is a very early, small Phase 1 trial focused on safety and dosing, not yet on effectiveness. The therapy may not shrink tumors or improve survival, and there are risks of serious side effects from the CAR T-cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MALIGNANT GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted drug aims to shrink recurrent brain tumors by blocking key growth enzyme
- Immunotherapy drug nivolumab tested in young brain cancer patients
- Promising drug combo targets aggressive brain cancers in youth
- Brain radiation showdown: proton vs. photon – which saves your mind?
- Targeted drug shows promise for kids with tough cancers
- New hope for kids with Hard-to-Treat cancers: targeted drug shows promise